The FDA approved dabigatran etexilate as the first oral blood thinner for children aged 3 months to 11 years who have venous thromboembolism and received injectable blood thinners for at least 5 days. Previously, the only anticoagulant approved for children was an injectable formulation.
“The FDA is committed to helping our youngest patients with serious medical conditions have treatments that are relatively easy to take,” Ann Farrell, MD, director of the FDA’s Division of Non-Malignant Hematology, said in a statement.
Kuehn BM. First Oral Blood Thinner Is Approved for Children. JAMA. 2021;326(7):593. doi:10.1001/jama.2021.13259
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: